The clinical trial of the first phase of nasal jets of the University of Hong Kong has been completed, and no major adverse reactions were found.
According to the Hong Kong News Agency, Lu Chongmao, the Hong Kong Medical Health Director, said on Wednesday (November 30) that this clinical trial has been completed among 29 volunteers aged 18 to 55.The discovery of major adverse reactions means that the vaccine can be safely used in humans.
Lu Chongmao said that the clinical test of the second phase of the vaccine has been conducted in more than 100 volunteers aged 18 to 75. The research team is currently collecting immune data and analysis. It is expected to be in the first quarter of next year.Finish.
The Medical and Health Bureau's Medical and Health Research Fund under the jurisdiction of the Medical and Health Bureau has approved a total of 29.5 million yuan (HK $ 5.14 million) for funding from April 2020. It supports two universities in Hong Kong to carry out four R & D vaccinesRelated projects.
